Eli Lilly (LLY) Q2 2026 earnings review
Incretin Juggernaut Overpowers Massive Pricing Headwinds
Lilly is operating in a league of its own. Q2 2026 revenue surged 48% YoY to $23.0 billion, obliterating estimates despite a severe 13% global price decline. The volume growth (+60%) is entirely offsetting aggressive rebate and international pricing dynamics. Mounjaro and Zepbound combined for an astonishing $14.87 billion, now representing nearly 65% of the company's total top line. Management confidently raised FY26 revenue guidance by $2 billion at the midpoint to $85.0-$87.0 billion. While acquired IPR&D heavily impacted GAAP EPS, underlying operational leverage is spectacular, with non-GAAP gross margins expanding to 86.3%.
🐂 Bull Case
The sheer scale of demand is neutralizing any pricing concerns. Global volume grew 60% YoY, driving an all-in 48% top-line expansion. The incretin market is still in its early innings of penetration.
Despite investing heavily in pipeline and launches, gross margin improved by 130 basis points to 86.3%. Economies of scale in manufacturing are translating volume directly to the bottom line.
🐻 Bear Case
Outside the U.S., realized prices plummeted 36% in Q2, heavily impacted by Mounjaro's inclusion on China's NRDL. Lilly must sustain extreme volume growth to make the international business economically attractive long-term.
A $2.8 billion IPR&D charge erased $3.03 from EPS this quarter. While Lilly is acquiring valuable next-gen assets, this aggressive M&A cadence consistently disrupts bottom-line predictability.
⚖️ Verdict: 🟢🟢
Extremely Bullish. A 48% top-line growth rate at a $90 billion run-rate is historic. The company is easily absorbing aggressive pricing headwinds and M&A costs while structurally raising its core guidance.
Key Themes
Mounjaro and Zepbound: The Twin Engines
Mounjaro revenue accelerated to $9.94B (+91% YoY), while Zepbound hit $4.93B (+46% YoY). The growth is strictly volume-driven, with U.S. volume up 37% and outside-U.S. volume exploding by 113%. This duopoly now dictates the entirety of Lilly's commercial trajectory.
Operating Leverage & Production Efficiencies
Non-GAAP gross margin is accelerating, hitting 86.3% (up 1.3 points YoY). Management explicitly credited 'improved cost of production and favorable product mix.' As massive new facilities come online, unit economics are improving faster than price degradation is hurting them.
Aggressive Business Development Strategy
Lilly is heavily deploying its incretin cash flow to buy future pipelines. Q2 saw acquisitions of Orna, Ajax, Centessa, and Kelonia, plus post-quarter agreements for AtaiBeckley and infectious disease assets. This signifies a clear shift to diversify away from purely cardio-metabolic reliance.
The Price vs. Volume Divergence
While the top-line narrative is flawless, the underlying mechanics show a decelerating pricing environment. Global prices fell 13%. More concerningly, OUS prices collapsed 36% due to China NRDL dynamics. Lilly reported an 80% OUS revenue gain, but this required an exhausting 113% volume increase just to overcome the pricing gap.
Next-Generation Genetic Breakthroughs
Moving beyond GLP-1s, Lilly highlighted VERVE-102, a PCSK9 base editor that reduced LDL-C by up to 62% via a single dose. This represents a massive technological innovation shifting chronic cardiovascular care toward one-time genetic cures.
U.S. Access and Medicare Expansion
The U.S. pricing environment (-3% realized price) reflects a managed transition. The decline was driven by Zepbound cash-pay reductions and Trulicity/incretin rebates. This is a deliberate strategy to widen the funnel for broader Medicare Part D inclusion and employer access, prioritizing lifetime patient value over spot pricing.
Acquired IPR&D Masking Core Profitability
The structural habit of booking massive IPR&D charges is penalizing statutory results. A $2.8 billion Q2 hit lowered reported and non-GAAP EPS by $3.03. While the underlying EPS guide was raised by $2.78, the optical range was lowered to $35.50-$36.50. Investors must continually manually adjust earnings to assess true operating performance.
Other KPIs
Accelerating significantly at +80% YoY, outstripping the U.S. growth rate of 33%. The OUS footprint is rapidly becoming a secondary pillar for the incretin franchise, driven by rapid launch uptake despite aggressive governmental price controls.
Grew 14% YoY, representing 17% of total revenue. Even with explosive top-line growth, Lilly is maintaining absolute R&D discipline, keeping the percentage of revenue highly stable to fund the retatrutide and orforglipron (Foundayo) late-stage programs.
Guidance
Accelerating. The midpoint of $86.0B implies ~32% YoY growth from FY25's $65.2B. This is a massive $2 billion raise from the Q1 estimate ($83.5B midpoint), signaling total confidence in manufacturing supply and prescription durability through the second half of the year.
Stable optically, but structurally Accelerating. The range incorporates the $3.03 Q2 IPR&D penalty. However, management noted that underlying operating EPS was raised by $2.78. Stripping out M&A noise, the core earning power is dramatically outperforming expectations.
Accelerating. Raised significantly from the previous 47.0%-48.5% range. This highlights profound operating leverage; the incremental revenue from Mounjaro and Zepbound is dropping straight to the bottom line.
Key Questions
OUS Price Floor
With OUS prices dropping 36% largely due to the China NRDL, where is the floor for international pricing, and at what point does the volume required to offset these cuts strain our manufacturing network?
Orforglipron Cannibalization
As the U.S. submission for orforglipron (Foundayo) in T2D is now underway, what percentage of its early volume is expected to be market-expansive versus cannibalizing Mounjaro or Zepbound?
Capital Allocation Shift
Given the sheer volume of Q2 M&A deals in immunology and neuroscience, is the focus officially shifting away from cardiometabolic bolt-ons, or is this just opportunistic pipeline filling?